

Gurudatta naik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1084271/publications.pdf>

Version: 2024-02-01

46
papers

8,585
citations

304743

22
h-index

214800

47
g-index

48
all docs

48
docs citations

48
times ranked

15489
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 439-458.	10.2	2,005
2	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 88-106.	10.2	1,512
3	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 56-87.	10.2	1,064
4	Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 585-596.	10.7	1,049
5	The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 42-54.	8.1	390
6	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 934-947.	8.1	372
7	Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 376-393.	10.2	359
8	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , the, 2019, 6, e831-e859.	4.7	341
9	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 913-933.	8.1	259
10	The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 582-597.	8.1	241
11	Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2018, 17, 1061-1082.	10.2	221
12	The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis. <i>The Lancet Global Health</i> , 2020, 8, e1186-e1194.	6.3	98
13	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018, 124, 2115-2124.	4.1	79
14	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	7.0	74
15	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.4	44
16	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	4.1	38
17	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. <i>Molecular Cancer Research</i> , 2019, 17, 84-96.	3.4	37
18	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. <i>PLoS ONE</i> , 2015, 10, e0139267.	2.5	34

#	ARTICLE	IF	CITATIONS
19	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 136-145.	4.4	33
20	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020, 3, 695-699.	5.4	30
21	Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC. <i>Cancer Research</i> , 2019, 79, 1413-1425.	0.9	27
22	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 624-633.	1.9	25
23	Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Oncology Research and Treatment</i> , 2014, 37, 772-776.	1.2	23
24	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or 3rd) Line of Therapy. <i>Urology</i> , 2019, 124, 487.	3.5	23
25	Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. <i>PLoS ONE</i> , 2016, 11, e0160924.	2.5	20
26	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020, 39, 4077-4091.	5.9	19
27	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , 2018, 4, 733-736.	3.1	18
28	Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 464-473.	1.4	16
29	Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. <i>Oncotarget</i> , 2017, 8, 21710-21718.	1.8	14
30	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 253-261.	4.4	13
31	Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. <i>FASEB Journal</i> , 2017, 31, 1608-1619.	0.5	11
32	Fatty liver index and risk of diabetes incidence: A systematic review and dose-response meta-analysis of cohort studies. <i>Primary Care Diabetes</i> , 2020, 14, 577-583.	1.8	10
33	Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008824.	3.0	10
34	Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 29220-29232.	1.8	10
35	Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes. <i>Cancer Causes and Control</i> , 2018, 29, 333-342.	1.8	8
36	Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 2.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 469-475.	1.9	7
38	Disparities in hospitalization outcomes among African-American and White prostate cancer patients. <i>Cancer Epidemiology</i> , 2017, 46, 73-79.	1.9	7
39	Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100589.	1.1	7
40	So You Want to Be a Principal Investigator. <i>Journal of Oncology Practice</i> , 2018, 14, e384-e392.	2.5	6
41	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461.	4.1	6
42	Hospitalization outcomes and racial disparities in cervical cancer patients: An analysis of the national inpatient sample data from 2002 to 2014. <i>Cancer Epidemiology</i> , 2019, 63, 101620.	1.9	4
43	Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. <i>Oncologist</i> , 2020, 25, e1628-e1639.	3.7	4
44	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 534-539.	1.9	3
45	Sequential matched analysis of racial disparities in breast cancer hospitalization outcomes among African American and White patients. <i>Cancer Epidemiology</i> , 2017, 49, 138-143.	1.9	3
46	Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa. <i>Current Breast Cancer Reports</i> , 2019, 11, 158-169.	1.0	1